Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation
The causation theory for injuries related to Stryker Rejuvenate and ABG II Hip Implants centers on corrosion mechanisms at modular junctions, leading to metal ion release, metallosis, pseudotumor formation, tissue necrosis, and implant failure. Elevated cobalt and chromium levels, typically above approximately 7 ng/mL, are associated with adverse local tissue reactions. These failure mechanisms are supported by scientific studies and FDA recall notices, which highlight corrosion, fretting, and mechanical wear as primary causes of device failure.
6
Pending actions
3,638
Total actions filed
Active
Status
06/12/2013
Established
Filing deadline
The most recent court order from February 2026 set a response deadline of February 26, 2026, for certain claims. Past settlement claims submission deadlines included March 1, 2017. Statutes of limitations are generally 2-4 years from injury discovery but are not explicitly detailed in the court documents.
Who qualifies
Plaintiffs typically qualify if they underwent implantation of the Stryker Rejuvenate or ABG II devices within a specified period, experienced revision surgery related to device failure, and suffered injuries such as metallosis, pseudotumor, or elevated metal ion levels. Exact implant and revision dates, as well as specific diagnostic thresholds, are not explicitly detailed in the court documents but are generally inferred from settlement notices and medical standards.
Products involved
- Stryker Rejuvenate Hip Implant
- ABG II Modular Hip Stem
Alleged injuries
- metallosis
- pseudotumor formation
- elevated metal ion levels (cobalt, chromium)
- tissue necrosis
- implant loosening
- device failure
Bellwether trials
Active case management with scheduled proceedings in 2026; recent court orders from late January and February 2026 indicate ongoing scheduling and trial preparations. Specific trial dates are not explicitly listed but are likely to follow the latest management orders. No recent verdicts are reported, but ongoing activity suggests upcoming bellwether trials.
Settlement landscape
A settlement exceeding $1 billion was announced in 2014, with claims submission deadlines around March 1, 2017. The ongoing litigation involves active case management, with no recent verdicts reported but scheduled trials in 2026.
Lead counsel
- Meshbesher & Spence, Ltd.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
